Literature DB >> 28501006

Liquid chromatography-mass spectrometry-based quantitative proteomics analysis reveals chondroprotective effects of astragaloside IV in interleukin-1β-induced SW1353 chondrocyte-like cells.

Huali Luo1, Ling Yao2, Yudi Zhang3, Rongheng Li4.   

Abstract

OBJECTIVE: Chondrocyte apoptosis played a key role on the progression of Osteoarthritis (OA). Safe and effective drugs are urgently needed for the treatment of OA. Previous study reported that Astragaloside IV (ASG-IV) had exerted a protective effect against articular cartilage degeneration by promoting rapid proliferation of chondrocyte. Therefore, the aim of our study is to explore the effects and mechanisms of ASG-IV in chondrocyte apoptosis.
METHODS: Isobaric Tags For Relative And Absolute Quantitation (iTRAQ)-based quantitative proteomics was used to quantitatively detect and map proteins in SW1353 chondrocyte-like cells pre-treated with ASG-IV or interleukin-1β (IL-1β) or ASG-IV+IL-1β. The iTRAQ-labeled peptides were fractionated by high-accuracy liquid chromatography-mass spectrometry (LC-MS). Cell apoptosis and differentially expressed proteins was detected by flow cytometry (FCM), quantitative real-time polymerase chain reaction (qRT-PCR), and western blotting, respectively.
RESULTS: The apoptosis of the IL-1β-induced SW1353 cells treated with ASG-IV was greatly inhibited. Bioinformatics analysis revealed that gamma actin 1 (ACTG1) and Yes Associated Protein 1 (YAP1), participating in the Hippo signaling pathway and Vitronectin (VTN) and Collagen Type I Alpha 1 Chain (COL1A1), involving in the extracellular matrix (ECM)-receptor interaction signaling pathway, were all significantly up-regulated in the IL-1β-induced SW1353 cells after treatment with ASG-IV. The qRT-PCR and Western blotting results confirmed the up-regulation of these four genes.
CONCLUSION: ASG-IV played a positive role in human osteoarthritic chondrocyte apoptosis, possibly through modulation of the Hippo signaling pathway by up-regulating YAP1and ACTG1 expression, and also by up-regulating VTN and COL1A1, which are involved in the ECM-receptor interaction pathway. Taken together, all the results suggested that ASG-IV had a novel therapeutic potential for the treatment of OA.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  ACTG1; Astragaloside IV; COL1A1; Osteoarthritis; VTN; YAP1

Mesh:

Substances:

Year:  2017        PMID: 28501006     DOI: 10.1016/j.biopha.2017.04.127

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Identification of key gene modules and transcription factors for human osteoarthritis by weighted gene co-expression network analysis.

Authors:  Xiang Gao; Yu Sun; Xu Li
Journal:  Exp Ther Med       Date:  2019-08-05       Impact factor: 2.447

2.  iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.

Authors:  Huali Chen; Mingjun Wu; Wei Jiang; Xiang Liu; Jun Zhang; Chao Yu
Journal:  Int J Mol Med       Date:  2020-01-22       Impact factor: 4.101

3.  Sex Differences in Osteoarthritis Pathogenesis: A Comprehensive Study Based on Bioinformatics.

Authors:  Yunfeng Yang; Xiaomeng You; Jordan Daniel Cohen; Haichao Zhou; Wenbao He; Zihua Li; Yuan Xiong; Tao Yu
Journal:  Med Sci Monit       Date:  2020-04-07

4.  Proteomic Analysis Reveals Commonly Secreted Proteins of Mesenchymal Stem Cells Derived from Bone Marrow, Adipose Tissue, and Synovial Membrane to Show Potential for Cartilage Regeneration in Knee Osteoarthritis.

Authors:  Yura Lee; Yo Seph Park; Na Young Choi; Yong Il Kim; Yong-Gon Koh
Journal:  Stem Cells Int       Date:  2021-06-28       Impact factor: 5.443

Review 5.  Yes-Associated Protein 1: Role and Treatment Prospects in Orthopedic Degenerative Diseases.

Authors:  Wenqing Xie; Wenfeng Xiao; Kun Tang; Liyang Zhang; Yusheng Li
Journal:  Front Cell Dev Biol       Date:  2020-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.